Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: A meta-analysis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Huang, Xuanzhang ^a   Gao, Peng ^a   Song, Yongxi ^a   Sun, Jingxu ^a   Chen, Xiaowan ^a   Zhao, Junhua ^a   Liu, Jing ^a   Xu, Huimian ^a   Wang, Zhenning ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Circulating tumor cells; Colorectal cancer; Prognosis; Tumor response

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ANTINEOPLASTIC AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924710322     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-976     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011,61(2):69-90. 10.3322/caac.20107
2. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007,370(9582):135-142. 10.1016/S0140-6736(07)61086-1
3. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007,370(9582):143-152. 10.1016/S0140-6736(07)61087-3
4. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008,26(14):2311-2319. 10.1200/JCO.2007.13.1193
5. Zinser-Sierra JW, Rodriguez-Ramirez S, Villalobos-Valencia R, Ramirez-Marquez M: Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R&D 2011,11(2):101-111. 10.2165/11590440-000000000-00000
6. Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G: KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012,107(4):626-631. 10.1038/bjc.2012.275
7. Vigano L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L: Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013,258(5):731-740. discussion 741-732 10.1097/SLA.0b013e3182a6183e
8. Sorbye H, Dahl O: Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 2003,21(23):4466-4467. 10.1200/JCO.2003.99.200
9. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr: Asco: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006,24(33):5313-5327. 10.1200/JCO.2006.08.2644
10. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004,351(8):781-791. 10.1056/NEJMoa040766
11. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008,26(19):3213-3221. 10.1200/JCO.2007.15.8923
12. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008,14(19):6302-6309. 10.1158/1078-0432.CCR-08-0872
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009,45(2):228-247. 10.1016/j.ejca.2008.10.026
14. Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010,25(9):603-605. 10.1007/s10654-010-9491-z
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009,6(7):e1000097. 10.1371/journal.pmed.1000097
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16. 10.1186/1745-6215-8-16
17. Chu H, Cole SR: Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006,59(12):1331-1332. author reply 1332-1333 10.1016/j.jclinepi.2006.06.011
18. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002,21(4):589-624. 10.1002/sim.1040
19. Schmidt FL, Oh IS, Hayes TL: Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol 2009,62(Pt 1):97-128.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003,327(7414):557-560. 10.1136/bmj.327.7414.557
21. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004,57(7):683-697. 10.1016/j.jclinepi.2003.12.001
22. Higgins J, Thompson S, Deeks J, Altman D: Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002,7(1):51-61. 10.1258/1355819021927674
23. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997,315(7109):629-634. 10.1136/bmj.315.7109.629
24. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994,50(4):1088-1101. 10.2307/2533446
25. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000,56(2):455-463. 10.1111/j.0006-341X.2000.00455.x
26. Sastre J, Maestro ML, Gomez-Espana A, Rivera F, Valladares M, Massuti B, Benavides M, Gallen M, Marcuello E, Abad A, Arrivi A, Fernandez-Martos C, Gonzalez E, Tabernero JM, Vidaurreta M, Aranda E, Diaz-Rubio E: Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012,17(7):947-955. 10.1634/theoncologist.2012-0048
27. de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf J, Breier G, Stamminger G, Fersis N, Kaul S: Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med 2012, 10:222. 10.1186/1479-5876-10-222
28. Matsusaka S, Suenaga M, Mishima Y, Kuniyoshi R, Takagi K, Terui Y, Mizunuma N, Hatake K: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci 2011,102(6):1188-1192. 10.1111/j.1349-7006.2011.01926.x
29. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, Vos AH, Nagtegaal ID, Terstappen LW, Punt CJ: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010,21(5):1006-1012. 10.1093/annonc/mdp463
30. Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, Cano A, Gomez-Tato A, de Los Angeles Casares de Cal M, Abal M, Lopez-Lopez R: A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. International journal of cancer Journal international du cancer 2014,135(11):2633-2643. 10.1002/ijc.28910
31. Staritz P, Kienle P, Koch M, Benner A, von Knebel DM, Rudi J, Weitz J: Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients. J Exp Clin Cancer Res 2004,23(4):633-639.
32. Yalcin S, Kilickap S, Portakal O, Arslan C, Hascelik G, Kutluk T: Determination of circulating tumor cells for detection of colorectal cancer progression or recurrence. Hepatogastroenterology 2010,57(104):1395-1398.
33. Konigsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, Dittrich C, Zeillinger R: Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett 2010,293(1):117-123. 10.1016/j.canlet.2010.01.003
34. Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res 2013,33(9):3905-3910.
35. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M: Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011,29(12):1547-1555. 10.1200/JCO.2010.30.5151
36. Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY: Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer 2013,108(4):791-797. 10.1038/bjc.2012.595
37. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY: Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009,15(13):4508-4513. 10.1158/1078-0432.CCR-08-3179
38. Oye RK, Shapiro MF: Reporting results from chemotherapy trials. Does response make a difference in patient survival? JAMA 1984,252(19):2722-2725. 10.1001/jama.1984.03350190024013
39. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Buchler MW, Koch M, Weitz J: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010,138(5):1714-1726. 10.1053/j.gastro.2010.01.008
40. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007,356(2):125-134. 10.1056/NEJMoa060655
41. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003,349(5):427-434. 10.1056/NEJMoa021491
42. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000,356(9227):373-378. 10.1016/S0140-6736(00)02528-9
43. Molnar B, Sipos F, Galamb O, Tulassay Z: Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 2003,21(4):320-325. 10.1159/000075355
44. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009,10(3):233-239. 10.1016/S1470-2045(08)70340-1
45. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, Voigt A, Kloor M, Benner A, Bork U, Rahbari NN, Buchler MW, Stoecklein NH, Weitz J, Koch M: Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014,74(6):1694-1704. 10.1158/0008-5472.CAN-13-1885